What is Streptococcus Pneumoniae Vaccine Market Scope?
The very first pneumococcal vaccine was made in the 1980s. It is on the list of the World Health Organization as one of the most important medicines. It is the safest and most effective medicine needed in any healthcare system. These vaccines are usually very safe. With this conjugated vaccine, nearly 10 percent of babies will develop redness at the injection site, difficulty sleeping, and sometimes a fever. Severe allergies are very rare. Pneumococcal vaccines are the vaccines that fight against the bacterium Streptococcus pneumoniae. The use of these can effectively prevent some cases of pneumonia, sepsis, and meningitis. Namely, there are two types of pneumococcal vaccines as conjugate vaccines and polysaccharide vaccines. These are given by injection either into a muscle area or just under the skin. The World Health Organization (WHO) commends the use of the conjugate vaccine in the routine immunization to be given to the children. This also includes people with HIV / AIDS. These vaccines are effective in healthy adults, but not entirely effective in children under the age of two and children with very poor immune function. In 2013, the World Health Organization and UNICEF launched a Global Plan of Action to Prevent and Control Pneumonia and Diarrhea (GAPPD), opening a new chapter in efforts to contain pneumonia. We are currently facing a whole new challenge, the COVID-19 pandemic. The coronavirus is responsible for respiratory illnesses and some of the infected leads develop pneumonia. Respiratory diseases such as COVID-19 very often spread through droplets from an infected person's sneeze or cough, or through contact with contaminated surfaces. Hence, poor hygiene or sanitation and overcrowding are some of the major drivers of transmission. Vaccines can prove to be one of the keys to prevention. They are the world's best for health and the very first line of defense against respiratory disease. Contrasted with the cheaper and available pneumonia vaccines like the pneumococcal vaccine, which are vital in releasing health resources and enabling herd immunity. Even so, the pneumonia vaccines like the pneumococcal vaccine do not offer protection against COVID-19. Although these vaccines are not very effective against COVID-19, vaccination against respiratory disease prevention is highly recommended for health protection. Due to the lower consumption and need for vaccines, the market is likely to grow very slowly. The global Streptococcus pneumoniae vaccine market was valued at USD 5,230 million in 2019 and is projected to reach USD 5,924.56 million by 2025, a CAGR of 2.1% from 2019 to 2025.
The Streptococcus Pneumoniae Vaccine market study is being classified by Type (Pneumococcal Conjugate Vaccine (PCV) and Pneumococcal Polysaccharide Vaccine (PPV)), by Application (Clinics and Hospitals) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from European will contribute to the maximum growth of Global Streptococcus Pneumoniae Vaccine market throughout the predicted period.
Pfizer (United States), Sanofi (France), GSK (United Kingdom), Merck Group (Germany), Eli Lilly and Company (United States), AstraZeneca (United Kingdom), Abera (Sweden), S K Chemicals (South Korea), Beijing Minhai Biotechnology (China), Baxter International (United States), BIKEN TECHNO CORPORATION LTD (Japan), Celgene (United States), Panacea Biotec (India), Serum Institute of India (India), Genentech (United States), Genocea Biosciences (United States) and Lupin Limited (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Nuron Biotech (United States), Biogen (United States), Valneva SE (France) and Sinovac Biotech (China).
Analyst at AMA have segmented the market study of Global Streptococcus Pneumoniae Vaccine market by Type, Application and Region.
On the basis of geography, the market of Streptococcus Pneumoniae Vaccine has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
On April 14th, 2020, Sanofi and GSK announced that they had signed a letter of intent to enter into a collaboration for the development of an adjuvant vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic. Sanofi would contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofiís licensed recombinant influenza product in the US. Whereas, GSK would contribute its proven pandemic adjuvant technology for the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people.
In July 2000, the American Academy of Pediatrics (AAP) and the CDC jointly recommended childhood pneumococcal immunization, since pneumococcal infections are the most common invasive bacterial infections in children in the United States. "The pneumococcal conjugate vaccine, PCV13 or Prevnar 13, is currently recommended for all children younger than 5 years of age, all adults 65 years or older, and persons 6 through 64 years of age with certain medical conditions," according to the 2014 AAP/CDC guidelines.
Influencing Market Trend
- The Growing Trend Of Easier Access To Healthcare Facilities And The Provision Of Low-Cost Pneumonia Vaccines Has Also Attracted Several Consumers Causing The Marketís Growth
- Rising Prevalence of the Disease
- Increase in Focus for Novel Pneumococcal Vaccines
- Growing Government Focus on Immunization Programs
- Awareness for Pneumococcal Disease
- Growing Awareness and Development of Newer Therapies with Minimum Invasive Nature
- The Development of the Protein Vaccines for Pneumococcal Diseases
- The Higher Costs That Are Associated With the Manufacturing of the Vaccines
- Lack of Awareness among the Older Population Regarding the Vaccines
Key Target AudienceManufacturers of Streptococcus Pneumoniae Vaccine, Suppliers and Distributors of Streptococcus Pneumoniae Vaccine, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.